Trial Profile
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin. A 52-week, Randomised, Double-blind, Placebo-controlled Trial (PIONEER 8 - Insulin add-on)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 8
- Sponsors Novo Nordisk
- 31 May 2023 Results of a post-hoc analysis from clinical trials: PIONEER 1-5 and 8 assessing clinically relevant composite endpoints of HbA1c (glyclated haemogloblin) reduction published in the Diabetes Therapy
- 07 Jun 2022 Results of post-hoc analysis of PIONEER 8 characterizing the transition of adding a GLP-1RA to insulin therapy and to quantify reductions in total insulin dose seen with the addition of oral semaglutide, presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 01 Dec 2021 Results of post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials assessing Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes published in the Diabetes, Obesity and Metabolism